Publication:
Optimal step doses for drug provocation tests to prove beta-lactam hypersensitivity

dc.contributor.authorA. M. Chiriacen_US
dc.contributor.authorT. Rerkpattanapipaten_US
dc.contributor.authorP. J. Bousqueten_US
dc.contributor.authorN. Molinarien_US
dc.contributor.authorP. Demolyen_US
dc.contributor.otherHopital Arnaud de Villeneuveen_US
dc.contributor.otherSorbonne Universiteen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherCHU Montpellieren_US
dc.contributor.otherUniversité de Montpellieren_US
dc.date.accessioned2018-12-21T08:00:43Z
dc.date.accessioned2019-03-14T08:03:51Z
dc.date.available2018-12-21T08:00:43Z
dc.date.available2019-03-14T08:03:51Z
dc.date.issued2017-04-01en_US
dc.description.abstract© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Background: Drug provocation tests (DPT) are commonly performed as part of β-lactam (BL) allergy workup, in case of negative skin tests (ST) and in the absence of contraindications. The recommendations of learned societies have created a frame for DPT performance, but protocols vary widely between centres, generating various hypothesis-driven protocols (i.e. empirical dosing, driven by both safety concerns and practical aspects). Methods: The primary objective of this retrospective analysis was to detect eliciting dose thresholds (reactive doses) during BL DPT, using the survival analysis method, in order to suggest optimal step doses. Our secondary objective was to evaluate the safety of our 30-min incremental 1-day protocol. The study included all the patients explored in the Allergy Unit of the University Hospital of Montpellier (France), between September 1996 and July 2015 for a suspicion of drug hypersensitivity reaction to BLs, with negative ST and positive DPT. Results: During the study period, 182 positive DPT (accounting for 171 hypersensitive patients) were analysed. We identified eliciting thresholds, and we suggest the following steps for DPT to BLs: 5–15–30–50% of daily therapeutic dose (with additional lower steps for index reactions of anaphylaxis). We confirm the safety of 1-day protocol for immediate and mild nonimmediate reactors, for both children and adults, with a surveillance period of 2 h after the last administered dose, and a prolonged surveillance after discharge of 48 h. Conclusion: This data-driven approach in designing DPT protocols is a step forward in improving DPT standardization, starting with the most frequently tested drugs, BL antibiotics.en_US
dc.identifier.citationAllergy: European Journal of Allergy and Clinical Immunology. Vol.72, No.4 (2017), 552-561en_US
dc.identifier.doi10.1111/all.13037en_US
dc.identifier.issn13989995en_US
dc.identifier.issn01054538en_US
dc.identifier.other2-s2.0-85005949140en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/42818
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85005949140&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.titleOptimal step doses for drug provocation tests to prove beta-lactam hypersensitivityen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85005949140&origin=inwarden_US

Files

Collections